NasdaqGS:ARWRBiotechs
Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options
Arrowhead Pharmaceuticals (NasdaqGS:ARWR) has entered into an exclusive worldwide license agreement with Madrigal Pharmaceuticals for its ARO-PNPLA3 RNAi therapeutic.
The deal covers development and commercialization of ARO-PNPLA3 for metabolic dysfunction-associated steatohepatitis, or MASH.
The agreement includes potential milestone and royalty revenues for Arrowhead tied to Madrigal’s progress with the program.
Arrowhead focuses on RNA interference therapies using its TRiM platform. MASH...